Cyprotex US celebrates Grand Opening of new facility in Framingham, MA




Hamburg, Germany, 27 April 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Cyprotex US, LLC, the US site of Cyprotex (a wholly owned subsidiary of Evotec), celebrated the grand opening of its new state-of-the-art facility in Framingham, MA, today. Evotec announced the relocation of Cyprotex US, LLC to the new 30,000 square feet facility at at 200 Staples Drive in Framingham, MA in February. 


Impressions of Grand Opening of new Cyprotex facility

After a brief address from Craig Johnstone, Chief Operating Officer of Evotec and Christopher Strock, Vice President of US ADMET Operations Cyprotex, Framingham’s Mayor Charlie Sisitsky officially opened the new facility by cutting the ribbon. During a subsequent tour of the facility, guests from leading pharmaceutical and biotech companies got a closer look at cutting-edge technologies in action.

Cyprotex’ new facility comprises the latest liquid handling automation and mass spectrometry technology, that translate to significant efficiency gains, higher capacity, and faster turnaround times. The new facility will offer a high-throughput alternative to its partners paving the way for significant further growth of its ADME-Tox services business for US-based customers.

Watch the Framingham Facility Tour

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “We are thrilled about the added value that the first-class scientific facility in Framingham will deliver to our clients across the US. Integrating predictive toxicology and ADME research into the R&D continuum is essential for cost-efficient development of new medicines. The expansion to Framingham represents our commitment to this vision and marks a significant milestone for Cyprotex.”

Dr Christopher Strock, VP of US ADMET Operations, Cyprotex, added: “We are excited to announce the opening of the new facility in Framingham, MA. Framingham is home to a thriving biotechnology ecosystem, making it an ideal place for Cyprotex to grow and thrive. I would like to express heartfelt thanks to Mayor Charlie Sisitsky for warmly welcoming into the community – and especially thank our dedicated staff for hard work during the relocation process.”



Established in 1999, Cyprotex Limited was acquired by Evotec ( in 2016. Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Framingham near Boston, USA. The company has dedicated and highly qualified employees with proven experience in a wide range of specialist techniques acquired across diverse industries. The majority of our clients focus in pharmaceutical research, however, we also support clients in the chemical, cosmetics and personal care, agrichemical and tobacco industries. Cyprotex specialises in in vitro and in silico ADME-Tox services. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during pre-clinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise. Further information on Cyprotex is available on our website at



This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.